You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,300,039


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,300,039
Title:Ferric citrate dosage forms
Abstract: Disclosed herein are ferric citrate-containing tablets. In various embodiments, the tablets include ferric citrate formulations that meet certain dissolution, tableting and disintegration standards. In various aspects, the tablet formulations can include ferric citrate as the active ingredient and a binder. The formulations also can include a lubricant and/or a disintegrant (which, in some embodiments, can be the same as the binder).
Inventor(s): Le; Henry Trong (Englewood Cliffs, NJ)
Assignee: KERYX BIOPHARMACEUTICALS, INC. (Boston, MA)
Application Number:15/159,008
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,300,039
Patent Claims: 1. A method for the prophylaxis or treatment of hyperphosphatemia comprising administering to a patient in need thereof a ferric citrate tablet, wherein the ferric citrate tablet comprises: (a) a core comprising approximately 90% to approximately 92% by weight of ferric citrate, approximately 4.5% to approximately 30% by weight of pregelatinized starch, and approximately 0.5% to approximately 3% by weight of a lubricant; and (b) a coating, wherein the tablet has a friability equal or less than 1% w/w, and wherein at least 80% of the ferric citrate in the tablet is dissolved in less than or equal to 60 minutes as measured by test method USP <711>, and the moisture content of the tablet is less than 10% by loss on drying (LOD).

2. The method of claim 1, wherein the lubricant is calcium stearate.

3. The method of claim 1, wherein the tablet comprises approximately 1000 mg of ferric citrate.

4. A method for the prophylaxis or treatment of hyperphosphatemia comprising administering to a patient in need thereof a ferric citrate tablet containing approximately 210 mg of ferric iron, wherein the ferric citrate tablet comprises: (a) a core comprising approximately 87.6% by weight of ferric citrate, approximately 10% by weight of pregelatinized starch, and approximately 2.4% by weight of calcium stearate; and (b) a coating, wherein the tablet has a friability equal or less than 1% w/w and a disintegration time less than 15 minutes, and wherein at least 80% of the ferric citrate in the tablet is dissolved in less than or equal to 60 minutes as measured by test method USP <711>, and the moisture content of the tablet is 8.84% (LOD).

5. A method for the prophylaxis or treatment of hyperphosphatemia comprising administering to a patient in need thereof a ferric citrate tablet, wherein the ferric citrate tablet comprises: (a) a core comprising approximately 90% to approximately 92% by weight of ferric citrate, approximately 4.5% to approximately 30% by weight of pregelatinized starch, and approximately 0.5% to approximately 3% by weight of a lubricant; and (b) a coating, wherein the tablet has a friability equal or less than 1% w/w, and wherein at least 80% of the ferric citrate is dissolved in less than or equal to 60 minutes as measured by test method USP <711>, and the moisture content of the tablet is between 5% to 10% by LOD.

6. The method of claim 5, wherein the lubricant is calcium stearate.

7. The method of claim 5, wherein the tablet comprises approximately 1000 mg of ferric citrate.

8. A method for the prophylaxis or treatment of hyperphosphatemia comprising administering to a patient in need thereof a ferric citrate tablet, wherein the ferric citrate tablet comprises: (a) a core comprising approximately 90% to approximately 92% by weight of ferric citrate, approximately 1.5% to approximately 15% by weight of pregelatinized starch, and approximately 0.5% to approximately 3% by weight of a lubricant; and (b) a coating, wherein the tablet has a friability equal or less than 1%, and wherein at least 80% of the ferric citrate in the tablet is dissolved in less than or equal to 60 minutes as measured by test method USP<711>, and the moisture content of the tablet is between 5% to 10% by LOD.

9. The method of claim 8, wherein the lubricant is calcium stearate.

10. The method of claim 8, wherein the tablet comprises approximately 1000 mg of ferric citrate.

11. A method for controlling serum phosphorus levels in an end-stage renal disease patient on hemodialysis comprising administering to the patent a ferric citrate tablet, wherein the ferric citrate tablet comprises: (a) a core comprising approximately 90% to approximately 92% by weight of ferric citrate, approximately 4.5% to approximately 30% by weight of pregelatinized starch, and approximately 0.5% to approximately 3% by weight of a lubricant; and (b) a coating, wherein the tablet has a friability equal or less than 1% w/w, and wherein at least 80% of the ferric citrate in the tablet is dissolved in less than or equal to 60 minutes as measured by test method USP <711>, and the moisture content of the tablet is less than 10% by loss on drying (LOD).

12. The method of claim 11, wherein the lubricant is calcium stearate.

13. The method of claim 11, wherein the tablet comprises approximately 1000 mg of ferric citrate.

14. A method for controlling serum phosphorus levels in an end-stage renal disease patient on hemodialysis comprising administering to the patent a ferric citrate tablet containing approximately 210 mg of ferric iron, wherein the ferric citrate tablet comprises: (a) a core comprising approximately 87.6% by weight of ferric citrate, approximately 10% by weight of pregelatinized starch, and approximately 2.4% by weight of calcium stearate; and (b) a coating, wherein the tablet has a friability equal or less than 1% w/w and a disintegration time less than 15 minutes, and wherein at least 80% of the ferric citrate in the tablet is dissolved in less than or equal to 60 minutes as measured by test method USP <711>, and the moisture content of the tablet is 8.84% (LOD).

15. A method for controlling serum phosphorus levels in an end-stage renal disease patient on hemodialysis comprising administering to the patent a ferric citrate tablet, wherein the ferric citrate tablet comprises: (a) a core comprising approximately 90% to approximately 92% by weight of ferric citrate, approximately 4.5% to approximately 30% by weight of pregelatinized starch, and approximately 0.5% to approximately 3% by weight of a lubricant; and (b) a coating, wherein the tablet has a friability equal or less than 1% w/w, and wherein at least 80% of the ferric citrate is dissolved in less than or equal to 60 minutes as measured by test method USP <711>, and the moisture content of the tablet is between 5% to 10% by LOD.

16. The method of claim 15, wherein the lubricant is calcium stearate.

17. The method of claim 15, wherein the tablet comprises approximately 1000 mg of ferric citrate.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.